



J. B. Chemicals & Pharmaceuticals Limited

J. B. Chemicals & Pharmaceuticals Limited
Announces Unaudited Financial Results
for the second quarter ended 30th September, 2007

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, October 30, 2007: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited financial results for the second quarter and half-year ended September 30, 2007.

The Company achieved a Net Sales of Rs. 16226.97 lakhs for the second quarter ended September 30, 2007, as compared with Rs. 14814.65 lakhs for the same period last year, registering a growth of 9.53%. Profit Before Interest, Depreciation and Tax (PBIDT) is Rs. 3993.26 lakhs (Rs. 3811.52 lakhs), registering an increase of 4.77%. Outgo on account of Interest is Rs. 429.84 lakhs (Rs. 251.97 lakhs). The Depreciation charge is Rs. 459.95 lakhs (Rs. 355.00 lakhs). Profit before Tax stood at Rs. 3103.47 lakhs (Rs. 3204.55 lakhs). The Provision for Taxation (Current) is Rs. 342.84 lakhs (Rs. 320.58 lakhs) and Fringe Benefit tax is Rs. 25.00 lakhs (Rs. 25.00 lakhs) and reversal of Deferred tax liability is Rs. 54.77 lakhs as against Deferred Tax of Rs. 101.22 lakhs for the same period last year. The Profit after Taxation for the year is Rs. 2790.40 lakhs (Rs. 2757.75 lakhs). The Basic & Diluted Earnings Per Share (FV Rs.2/-) for the second quarter ended September 30, 2007 is Rs. 3.31/- (Rs. 3.28/-).

Thus, In H1 (1stApril – 30thSeptember 2007), the Net Sales stood at Rs. 26764.06 lakhs, up 7.31% from Rs. 24940.01 lakhs in the previous year and PAT is Rs. 3097.55 lakhs as against Rs. 4058.87 lakhs. The basic and diluted Earnings Per Share (FV Rs.2/-) is Rs. 3.67/- (Rs. 4.83/-). The results of the first quarter have impacted the H1 results. However, the second quarter results on a standalone basis are comparable with the results of the similar period last year.

The second quarter earnings of the Company for FY 07-08 were affected due to appreciating rupee translating into lower export sales realization and foreign exchange fluctuation loss on realizations of receivables. Even though the Company's export Sales in US dollar terms grew to US\$ 26.00 Mn (US\$ 19.50 Mn) at an impressive rate of 33%, growth in export sales in rupee terms was only 19.60% on YOY basis. The appreciation of Rupee V/s US Dollar has adversely impacted the Company by Rs. 1596 lakhs.

The Company has already taken a number of corrective measures to achieve higher growth rates translating into improved business performance. The corrective steps taken by the Company includes (1) Higher forward cover by hedging more (2) improve overall efficiency (3) Raising funds in foreign currency (4) Better product mix (5) Increase in price of some of the branded export products (6) Ramping up of Domestic Sales.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its shares in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com

-- x --

For more details, please contact:

Beejal Desai
Vice President & Company Secretary
Head Investor Relations
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 2499 1311

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.